Psoriatic Arthritis

High Coronary Plaque Burden Is Independent of Metabolic Syndrome in Psoriatic Arthritis

High Coronary Plaque Burden Is Independent of Metabolic Syndrome in Psoriatic Arthritis

By

Psoriatic arthritis is associated with accelerated coronary plaque formation, particularly mixed plaques, independent of metabolic disease.

Increased HLA-B27 Associated With More Severe Sonographic Enthesitis in PsA

Increased HLA-B27 Associated With More Severe Sonographic Enthesitis in PsA

By

In patients with psoriatic arthritis, increasing levels of HLA-B27 are associated with more severe sonographic enthesitis.

Spondyloarthritis Increases Risk for Dysrhythmias and Aortic Regurgitation

Spondyloarthritis Increases Risk for Dysrhythmias and Aortic Regurgitation

By

The risk for aortic regurgitation and cardiac rhythm abnormalities was evaluated in a nationwide cohort of patients with spondyloarthritis.

Efficacy and Safety of Ixekizumab Evaluated in Active Psoriatic Arthritis

Efficacy and Safety of Ixekizumab Evaluated in Active Psoriatic Arthritis

By

Results from the phase 3 SPIRIT-P1 study show that treatment with ixekizumab every 2 or 4 weeks in patients with active psoriatic arthritis demonstrated sustained efficacy and a favorable safety profile.

Efficacy of Apremilast Monotherapy Assessed in Biologic-Naive Psoriatic Arthritis

Efficacy of Apremilast Monotherapy Assessed in Biologic-Naive Psoriatic Arthritis

By

Patients with psoriatic arthritis who are taking apremilast experienced early symptom relief and sustained clinical improvement through 1 year of treatment.

Hyperuricemia in Psoriatic Arthritis: Identifying Features to Improve Outcomes

Hyperuricemia in Psoriatic Arthritis: Identifying Features to Improve Outcomes

By

A cohort study was conducted to determine the long-term outcomes especially of cardiovascular and kidney diseases in patients with psoriatic arthritis with comorbid hyperuricemia.

Risk of Liver Disease Increased With Psoriatic Arthritis

Risk of Liver Disease Increased With Psoriatic Arthritis

By

There is a higher risk for liver disease in patients with inflammatory disorders.

JAK Inhibitors Now Approved For Treatment of Active Psoriatic Arthritis

JAK Inhibitors Now Approved For Treatment of Active Psoriatic Arthritis

By

The FDA has approved tofacitinib and tofacitinib extended release to treat active psoriatic arthritis.

Updating Treatment Strategies for PsA: Aiming for Minimal Disease Activity

Updating Treatment Strategies for PsA: Aiming for Minimal Disease Activity

By

Rapid expansion of effective therapies for psoriatic arthritis has driven new, ambitious treatment targets of minimal disease activity and disease remission.

Overlap Between Remission and Low Disease Activity Targets in Psoriatic Arthritis

Overlap Between Remission and Low Disease Activity Targets in Psoriatic Arthritis

By

Investigators compared composite scores defining low disease activity state or remission in an existing real-life data set of patients with PsA.

Examining the Implications of Accelerated Coronary Plaque Formation in Psoriatic Arthritis

Examining the Implications of Accelerated Coronary Plaque Formation in Psoriatic Arthritis

By

Disease severity and activity in psoriatic arthritis may predict coronary plaque burden better than traditional risk factors.

Characterization of Rheumatic Disorders Associated With Immune Checkpoint Inhibitor Use

Characterization of Rheumatic Disorders Associated With Immune Checkpoint Inhibitor Use

By

A prospective, observational study sought to evaluate and characterize the nature of rheumatic disorders associated with immune checkpoint inhibitors.

CV Risk Scores Underestimate Subclinical Atherosclerosis in Psoriatic Arthritis

CV Risk Scores Underestimate Subclinical Atherosclerosis in Psoriatic Arthritis

By

Cardiovascular risk assessment tools in patients with PsA have been shown to underestimate the risk for carotid subclinical atherosclerosis.

Examining Smoking Paradox in PsA Development for Patients With Psoriasis

Examining Smoking Paradox in PsA Development for Patients With Psoriasis

By

Smoking is positively associated with the risk for PsA in the general population, but negatively associated with PsA in patients with psoriasis.

Psoriatic Arthritis Questionnaire Reliable, Feasible in Clinical Practice

Psoriatic Arthritis Questionnaire Reliable, Feasible in Clinical Practice

By

The Psoriatic Arthritis Impact of Disease Questionnaire is a reliable patient-reported outcome measure with utility among patients with psoriatic arthritis in clinical practice.

FDA Approves Ixekizumab for Treatment of Active Psoriatic Arthritis in Adults

FDA Approves Ixekizumab for Treatment of Active Psoriatic Arthritis in Adults

By

The FDA has approved ixekizumab for the treatment of adults with psoriatic arthritis.

Discontinuation of Biosimilar Infliximab Associated With Subjective Complaints

Discontinuation of Biosimilar Infliximab Associated With Subjective Complaints

By

Transitioning from an originator agent to its biosimilar has the potential to reduce healthcare costs without compromising outcomes.

Endothelial Function Improves With Methotrexate, Anti-TNF Therapy in Inflammatory Arthritis

Endothelial Function Improves With Methotrexate, Anti-TNF Therapy in Inflammatory Arthritis

By

Although the effect of antirheumatic drugs on inflammatory arthritic conditions has not been fully elucidated, treatment with methotrexate and tumor necrosis factor inhibitors has been found to improve endothelial dysfunction in this population.

Tumor Necrosis Factor Inhibitor Persistence in Patients with Psoriatic Arthritis

Tumor Necrosis Factor Inhibitor Persistence in Patients with Psoriatic Arthritis

By

TNFi persistence and factors influencing persistence were investigated in patients who were treated with TNFi therapy for the first time.

Tofacitinib or Adalimumab vs Placebo for Patients With Psoriatic Arthritis

Tofacitinib or Adalimumab vs Placebo for Patients With Psoriatic Arthritis

By

Tofacitinib may provide an alternate therapeutic mechanism of action for patients with psoriatic arthritis who have failed prior treatment with conventional synthetic disease-modifying antirheumatic drugs.

Abatacept Improves Outcomes in Patients With Active Psoriatic Arthritis

Abatacept Improves Outcomes in Patients With Active Psoriatic Arthritis

By

Administration of abatacept may improve patient-reported outcomes in individuals with active psoriatic arthritis and elevated levels of C-reactive protein, irrespective of tumor necrosis factor inhibitor treatment history.

Draft Psoriatic Arthritis Guideline Presented at ACR 2017

Draft Psoriatic Arthritis Guideline Presented at ACR 2017

By

The guideline includes recommendations for treating adult patients with active psoriatic arthritis.

Secukinumab Effective for Inhibiting Radiographic Progression in PsA

Secukinumab Effective for Inhibiting Radiographic Progression in PsA

By

Regardless of dose, patients taking secukinumab were more likely to experience no radiographic progression compared with placebo.

Rebound in Disease Activity in Patients With PsA After TNFi Discontinuation

Rebound in Disease Activity in Patients With PsA After TNFi Discontinuation

By

The risk for symptom flares is substantial after TNFi discontinuation in patients with psoriatic arthritis who had achieved remission/low disease activity.

Tofacitinib Improves Patient-Reported Outcomes for Active Psoriatic Arthritis

Tofacitinib Improves Patient-Reported Outcomes for Active Psoriatic Arthritis

By

Results from phase 3 trials OPAL Broaden (NCT01877668) and OPAL Beyond (NCT01882439) presented at the American College of Rheumatology 2017 in San Diego, California.

Therapeutic Goal Achievement Independent of Cardiovascular Risk in Psoriatic Arthritis

Therapeutic Goal Achievement Independent of Cardiovascular Risk in Psoriatic Arthritis

By

With the exception of sedentary lifestyle, cardiovascular risk factors were not found to impact the likelihood of achieving minimal disease activity among patients with psoriatic arthritis.

Higher Prevalence of Depression, ADHD Observed Among Women With Psoriatic Arthritis

Higher Prevalence of Depression, ADHD Observed Among Women With Psoriatic Arthritis

By

Researchers observed a higher prevalence of psychiatric disorders among female patients with psoriatic arthritis.

Secukinumab Effectively Inhibits Radiographic Progression of PsA

Secukinumab Effectively Inhibits Radiographic Progression of PsA

By

Regardless of dose, patients taking secukinumab were more likely to experience no radiographic progression compared with placebo.

Tofacitinib Safety Comparable With Biologics

Tofacitinib Safety Comparable With Biologics

By

The real-world rates of most adverse events in patients with psoriatic arthritis receiving several biologics may be comparable with those reported in phase 3 studies of tofacitinib.

Pregnancy Outcomes in SLE vs Other Connective Tissue, Inflammatory Rheumatic Conditions

Pregnancy Outcomes in SLE vs Other Connective Tissue, Inflammatory Rheumatic Conditions

By

Real-world data indicate that although most patients with systemic lupus erythematosus or connective tissue diseases have successful pregnancies, more adverse pregnancy outcomes occur.

Sign Up for Free e-newsletters